MRVI - Maravai LifeSciences Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.25
DETAILS
HIGH:
$6.00
LOW:
$4.50
MEDIAN:
$5.25
CONSENSUS:
$5.25
UPSIDE:
19.32%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 185.7 | 259.2 | 288.9 | 883.0 | 799.2 | 284.1 | 143.1 | 123.8 |
| Cost of Revenue | 152.4 | 150.9 | 148.7 | 169.0 | 140.6 | 79.6 | 66.8 | 60.8 |
| Gross Profit | 33.4 | 108.3 | 140.2 | 714.0 | 658.7 | 204.4 | 76.3 | 63.1 |
| Operating Expenses | ||||||||
| R&D Expenses | 23.3 | 19.2 | 17.3 | 18.4 | 15.2 | 9.3 | 3.6 | 4.5 |
| SG&A Expenses | 171.5 | 161.8 | 151.4 | 129.3 | 100.1 | 94.2 | 48.4 | 41.2 |
| Other Expenses | (154.7) | 162.9 | 3.2 | (7.8) | (11.2) | (19.0) | 0.3 | 0.1 |
| Operating Expenses | 40.1 | 343.9 | 171.8 | 139.8 | 104.0 | 84.5 | 52.3 | 45.7 |
| Operating Income | ||||||||
| Operating Income | (6.7) | (235.6) | (31.6) | 574.2 | 554.6 | 119.9 | 24.0 | 16.4 |
| Interest Expense | 27.0 | 47.7 | 45.9 | 20.4 | 30.3 | 30.7 | 30.0 | 27.4 |
| Interest Income | 23.9 | 27.4 | 27.7 | 2.3 | 0 | 0 | 0 | 0 |
| Profitability | ||||||||
| EBITDA | (147.1) | (156.9) | 712.4 | 610.0 | 585.8 | 138.3 | 48.2 | 33.2 |
| EBIT | (208.0) | (213.8) | 663.6 | 571.9 | 561.0 | 112.4 | 24.1 | 10.9 |
| Income Before Tax | (235.0) | (261.5) | 617.7 | 551.5 | 530.8 | 81.7 | (5.9) | (16.5) |
| Income Tax Expense | (4.2) | (1.9) | 756.1 | 60.8 | 61.5 | 2.9 | (0.7) | 0.4 |
| Net Income | (130.8) | (144.8) | (119.0) | 220.2 | 182.0 | 76.9 | (8.5) | (17.7) |
| Per Share Data | ||||||||
| EPS (Basic) | -0.91 | -1.05 | -0.90 | 1.67 | 1.59 | 7.43 | -0.05 | -0.20 |
| EPS (Diluted) | -0.91 | -1.05 | -0.90 | 1.67 | 1.56 | 2.36 | -0.05 | -0.20 |
| Shares Outstanding | 145.1 | 137.9 | 131.9 | 131.5 | 114.8 | 96.6 | 96.6 | 89.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 216.9 | 322.4 | 575.0 | 632.1 | 551.3 | 236.2 | 24.7 | 21.9 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 25.5 | 38.5 | 55.7 | 146.8 | 117.5 | 51.0 | 18.0 | 16.0 |
| Inventory | 40.5 | 50.1 | 51.4 | 43.2 | 51.6 | 33.3 | 14.2 | 14.3 |
| Other Current Assets | 13.4 | 18.1 | 17.8 | 25.8 | 0 | 0 | 0.8 | 0 |
| Total Current Assets | 296.3 | 429.1 | 699.9 | 847.9 | 740.0 | 331.6 | 60.6 | 53.8 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 1.2 | 217.0 | 222.6 | 116.6 | 95.4 | 101.3 | 94.3 | 42.6 |
| Goodwill | 129.4 | 159.9 | 326.0 | 283.7 | 152.8 | 224.3 | 224.3 | 224.3 |
| Intangible Assets | 151.5 | 195.0 | 221.0 | 216.7 | 117.6 | 177.7 | 197.9 | 218.1 |
| Long-Term Investments | 0 | 0 | 8.6 | 11.4 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 192.1 | 7.2 | 9.3 | 40.3 | 4.4 | 4.2 | 0.8 | 0.9 |
| Total Non-Current Assets | 474.3 | 579.1 | 787.5 | 1,434.4 | 1,178.2 | 939.1 | 517.2 | 485.9 |
| Total Assets | 770.6 | 1,008.2 | 1,487.5 | 2,282.3 | 1,918.3 | 1,270.7 | 577.8 | 539.7 |
| Current Liabilities | ||||||||
| Account Payables | 0 | 12.0 | 10.7 | 6.0 | 8.2 | 3.0 | 7.5 | 3.6 |
| Short-Term Debt | 5.4 | 5.4 | 5.4 | 5.4 | 6 | 6 | 2.5 | 2.5 |
| Deferred Revenue | 0 | 3.3 | 3.4 | 3.1 | 12.6 | 78.1 | 0.8 | 1.1 |
| Other Current Liabilities | 39.5 | 0 | 47.6 | 69.5 | 18.9 | 4.2 | 11.1 | 22.2 |
| Total Current Liabilities | 44.9 | 57.0 | 87.5 | 110.1 | 93.8 | 130.8 | 29.6 | 35.9 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 30.1 | 290.5 | 518.7 | 522.0 | 524.6 | 528.6 | 334.8 | 335.6 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 8.6 | 14.7 | 15.9 |
| Other Non-Current Liabilities | 322.8 | 11.1 | 12.0 | 693.4 | 713.6 | 391.8 | 1.2 | 2.5 |
| Total Non-Current Liabilities | 352.9 | 374.1 | 610.1 | 1,266.9 | 1,279.1 | 985.2 | 403.6 | 355.7 |
| Total Liabilities | 397.9 | 431.0 | 697.6 | 1,377.1 | 1,372.9 | 1,115.9 | 433.2 | 391.7 |
| Stockholders' Equity | ||||||||
| Common Stock | 2.6 | 2.5 | 2.5 | 2.6 | 2.6 | 2.6 | 183.9 | 182.8 |
| Retained Earnings | 10.1 | 140.9 | 285.7 | 404.8 | 184.6 | 0.9 | (42.4) | (38.2) |
| Accumulated Other Comprehensive Income | 0.5 | 0 | 0 | 0 | 0 | (0.0) | (0.1) | (0.2) |
| Total Stockholders' Equity | 212.4 | 325.3 | 416.8 | 545.2 | 315.5 | 88.5 | 141.4 | 144.4 |
| Total Liabilities & Equity | 770.6 | 1,008.2 | 1,487.5 | 2,282.3 | 1,918.3 | 1,270.7 | 577.8 | 539.7 |
| Debt Metrics | ||||||||
| Total Debt | 35.6 | 376.7 | 611.0 | 585.3 | 575.2 | 590.8 | 390.2 | 339.9 |
| Net Debt | (181.3) | 54.3 | 36.0 | (46.9) | 23.9 | 354.6 | 365.5 | 318.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | (130.8) | (259.6) | (119.0) | 490.7 | 469.2 | 78.8 | (5.2) | (16.9) |
| Depreciation & Amortization | 60.5 | 56.9 | 48.8 | 38.1 | 24.8 | 25.8 | 24.1 | 22.3 |
| Stock-Based Compensation | 0 | 49.4 | 34.6 | 18.7 | 10.5 | 24.6 | 1.7 | 2.1 |
| Change in Working Capital | (8.0) | (12.6) | 97.8 | (45.1) | (176.6) | 35.9 | 2.3 | (15.8) |
| Other Non-Cash Items | 20.7 | 171.1 | (690.9) | (8.7) | (6.2) | (7.5) | 2.4 | 7.8 |
| Operating Cash Flow | (57.6) | 7.5 | 126.2 | 536.0 | 368.6 | 152.2 | 24.1 | (0.2) |
| Investing Activities | ||||||||
| Capital Expenditure | (13.1) | (29.7) | (65.6) | (17.1) | (14.8) | (25.4) | (17.1) | (3.6) |
| Acquisitions | (18.3) | 0 | (69.6) | (238.3) | 120.0 | (3.0) | 0 | 0.2 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 5.3 | 12.9 | (12.2) | 0.5 | 34.5 | 0 | 0.2 |
| Investing Cash Flow | (31.4) | (24.3) | (122.3) | (267.6) | 105.7 | 6.1 | (17.1) | (3.5) |
| Financing Activities | ||||||||
| Net Debt Issuance | (5.4) | (234.1) | (5.8) | (5.4) | (6) | 196.9 | (2.6) | 55.4 |
| Stock Repurchased | 0 | (2.1) | (0.0) | 0 | 0 | (1,458.0) | (0.2) | (0.0) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (52.1) |
| Other Financing Activities | (11.1) | 0.4 | (55.3) | (184.4) | (154.8) | (100.9) | (1.3) | (12.5) |
| Financing Cash Flow | (16.5) | (235.7) | (61.1) | (187.5) | (159.0) | 53.2 | (4.2) | (9.2) |
| Cash Position | ||||||||
| Net Change in Cash | (105.5) | (252.6) | (57.2) | 80.9 | 315.1 | 211.5 | 2.8 | (12.9) |
| Cash at Beginning | 322.4 | 575.0 | 632.1 | 551.3 | 236.2 | 24.7 | 21.9 | 34.7 |
| Cash at End | 216.9 | 322.4 | 575.0 | 632.1 | 551.3 | 236.2 | 24.7 | 21.9 |
| Free Cash Flow | (70.7) | (22.2) | 60.7 | 518.9 | 353.7 | 126.8 | 7.0 | (3.8) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 185.7 | 259.2 | 288.9 | 883.0 | 799.2 | 284.1 | 143.1 | 123.8 |
| Gross Profit | 33.4 | 108.3 | 140.2 | 714.0 | 658.7 | 204.4 | 76.3 | 63.1 |
| Operating Income | (6.7) | (235.6) | (31.6) | 574.2 | 554.6 | 119.9 | 24.0 | 16.4 |
| Net Income | (130.8) | (144.8) | (119.0) | 220.2 | 182.0 | 76.9 | (8.5) | (17.7) |
| EPS (Diluted) | -0.91 | -1.05 | -0.90 | 1.67 | 1.56 | 2.36 | -0.05 | -0.20 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 216.9 | 322.4 | 575.0 | 632.1 | 551.3 | 236.2 | 24.7 | 21.9 |
| Total Assets | 770.6 | 1,008.2 | 1,487.5 | 2,282.3 | 1,918.3 | 1,270.7 | 577.8 | 539.7 |
| Total Debt | 35.6 | 376.7 | 611.0 | 585.3 | 575.2 | 590.8 | 390.2 | 339.9 |
| Stockholders' Equity | 212.4 | 325.3 | 416.8 | 545.2 | 315.5 | 88.5 | 141.4 | 144.4 |
| Cash Flow | ||||||||
| Operating Cash Flow | (57.6) | 7.5 | 126.2 | 536.0 | 368.6 | 152.2 | 24.1 | (0.2) |
| Capital Expenditure | (13.1) | (29.7) | (65.6) | (17.1) | (14.8) | (25.4) | (17.1) | (3.6) |
| Free Cash Flow | (70.7) | (22.2) | 60.7 | 518.9 | 353.7 | 126.8 | 7.0 | (3.8) |